Showing results (1041-1050 of 1,069) with videos related to
Sort By:
Pageof 107
Neuropharmacology|January 10, 2016
In vitro pharmacological and rat pharmacokinetic characterization of LY3020371, a potent and selective mGlu2/3 receptor antagonistJeffrey M Witkin, Paul L Ornstein, Charles H Mitch, et al.Urologic Oncology|April 3, 2018
Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomyMoshe C Ornstein, Claudia Marcela Diaz-Montero, Patricia Rayman, et al.Urology|August 17, 2010
Does previous robot-assisted radical prostatectomy experience affect outcomes at robot-assisted radical cystectomy? Results from the International Robotic Cystectomy ConsortiumMatthew H Hayn, Nicholas J Hellenthal, Abid Hussain, et al.Infection|April 17, 2025
Towards shortening the duration of antibiotic therapy for Lyme borreliosis: a systematic review and meta-analysisAlice Raffetin, Anna J Henningsson, Katharina Ornstein, et al.Journal for Immunotherapy of Cancer|October 17, 2022
Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinomaLandon C Brown, Jason Zhu, Kunal Desai, et al.European Urology|May 4, 2010
The learning curve of robot-assisted radical cystectomy: results from the International Robotic Cystectomy ConsortiumMatthew H Hayn, Abid Hussain, Ahmed M Mansour, et al.The Journal of Pharmacology and Experimental Therapeutics|February 1, 2017
Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive N-Methyl-d-Aspartate Receptor Antagonist in Rodents: Evidence Supporting the Use of mGlu2/3 Antagonists, for the Treatment of DepressionJ M Witkin, S N Mitchell, K A Wafford, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2018
Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic TargetVadim S Koshkin, Jorge A Garcia, Jordan Reynolds, et al.Nature|July 1, 2026
Casdatifan shows durable response linked to HIF-2α biology in kidney cancerToni K Choueiri, Jamie Merchan, Amita Patnaik, et al.Nature Biotechnology|November 2, 2024
Development of compact transcriptional effectors using high-throughput measurements in diverse contextsJosh Tycko, Mike V Van, Aradhana, et al.Pageof 107